6 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 1 | Terminated 1 |
Follow CSL Behring: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects CSL760 - Coronavirus Disease 2019 (COVID-19) | Phase 1 | Terminated | CSL Behring | 12 | 2021-02-02 | 2021-12-10 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects CSL730, Placebo - Immune Complex-mediated Autoimmune Diseases | Phase 1 | Terminated | CSL Behring | 52 | 2020-09-23 | 2023-11-29 |
| CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 - Anemia, Sickle Cell | Phase 1 | Terminated | CSL Behring | 1 | 2019-10-02 | 2021-06-18 |
| Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults CSL730, Placebo - Healthy | Phase 1 | Terminated | CSL Behring | 26 | 2018-01-10 | 2021-06-03 |
| Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) ALD518 - Acute GvHD | Phase 1 / Phase 2 | Terminated | CSL Behring | 3 | 2012-03-01 | 2021-02-17 |
| Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Subcutaneous immunoglobulins - Myasthenia Gravis | Phase 1 | Terminated | St. Louis University | 4 | 2011-10-01 | 2019-04-03 |
Anemia, Sickle Cell (1) · COVID-19 (1) · Myasthenia Gravis (1)
Hizentra (1) · clazakizumab (1)
United States (3) · United Kingdom (2) · Australia (1) · Netherlands (1)
Ghazala Hayat, M.D. (1) · Jafar Kafaie, M.D. (1) · Javier San Martin, MD FRCP (1)
2017 (1), 2019 (1)